TY - JOUR
T1 - Efficacy and safety of mini-dose glucagon for treatment of nonsevere hypoglycemia in adults with type 1 diabetes
AU - T1D Exchange Mini-dose Glucagon Study Group
AU - Haymond, Morey W.
AU - DuBose, Stephanie N.
AU - Rickels, Michael R.
AU - Wolpert, Howard
AU - Shah, Viral N.
AU - Sherr, Jennifer L.
AU - Weinstock, Ruth S.
AU - Agarwal, Shivani
AU - Verdejo, Alandra S.
AU - Cummins, Martin J.
AU - Newswanger, Brett
AU - Beck, Roy W.
AU - Polsky, Sarit
AU - Beatson, Christie
AU - Brackett, Scott
AU - Toschi, Elena
AU - Edwards, Stephanie
AU - Castillo, Astrid Atakov
AU - Bzdick, Suzan
AU - Tichy, Eileen
AU - Zgorski, Melinda
AU - Steffen, Amy
AU - Markman, Eileen
AU - Dalton-Bakes, Cornelia
AU - Peleckis, Amy
AU - Prestrelski, Steve
AU - Strange, Poul
N1 - Publisher Copyright:
© Copyright 2017 Endocrine Society.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Context: Standard treatment of hypoglycemia is oral carbohydrate, but it often results in hyperglycemia and entails extra caloric intake. Objective: To evaluate low-dose glucagon to treat mild hypoglycemia in ambulatory adults with type 1 diabetes (T1D). Design: Randomized crossover trial (two 3-week periods). Setting: Five U.S. diabetes clinics. Patients: Twenty adults with T1D using an insulin pump and continuous glucose monitor (CGM) and experiencing frequent mild hypoglycemia. Intervention: Nonaqueous mini-dose glucagon (MDG) (150 μg) to treat nonsevere hypoglycemia. Main Outcome Measures: Successful treatment was defined as blood glucose (BG) ≥50 mg/dL 15 minutes and ≥70mg/dL 30 minutes after intervention, on the studymeter. Two authors, blinded to treatment arm, independently judged each event as a clinical success or failure. Results: Sixteen participants (mean age 39 years, 75% female, mean diabetes duration 23 years, mean hemoglobin A1c 7.2%) had 118 analyzable events with initial BG of 50 to 69 mg/dL. Successful treatment criteria were met for 58 (94%) of 62 events during the MDG period and 53 (95%) of 56 events during the glucose tablets (TABS) period (adjusted P = 0.99). Clinical assessments of success for these events were 97% and 96%, respectively. CGM-measured time in range did not differ between treatment groups during the 2 hours after events, but TABS resulted in higher maximum glucose (116 vs 102 mg/dL; P = 0.01) over the first hour. Conclusions: Low-dose glucagon can successfully treat mild hypoglycemia and may be a useful alternative to treatment with oral carbohydrate when trying to avoid unnecessary caloric intake.
AB - Context: Standard treatment of hypoglycemia is oral carbohydrate, but it often results in hyperglycemia and entails extra caloric intake. Objective: To evaluate low-dose glucagon to treat mild hypoglycemia in ambulatory adults with type 1 diabetes (T1D). Design: Randomized crossover trial (two 3-week periods). Setting: Five U.S. diabetes clinics. Patients: Twenty adults with T1D using an insulin pump and continuous glucose monitor (CGM) and experiencing frequent mild hypoglycemia. Intervention: Nonaqueous mini-dose glucagon (MDG) (150 μg) to treat nonsevere hypoglycemia. Main Outcome Measures: Successful treatment was defined as blood glucose (BG) ≥50 mg/dL 15 minutes and ≥70mg/dL 30 minutes after intervention, on the studymeter. Two authors, blinded to treatment arm, independently judged each event as a clinical success or failure. Results: Sixteen participants (mean age 39 years, 75% female, mean diabetes duration 23 years, mean hemoglobin A1c 7.2%) had 118 analyzable events with initial BG of 50 to 69 mg/dL. Successful treatment criteria were met for 58 (94%) of 62 events during the MDG period and 53 (95%) of 56 events during the glucose tablets (TABS) period (adjusted P = 0.99). Clinical assessments of success for these events were 97% and 96%, respectively. CGM-measured time in range did not differ between treatment groups during the 2 hours after events, but TABS resulted in higher maximum glucose (116 vs 102 mg/dL; P = 0.01) over the first hour. Conclusions: Low-dose glucagon can successfully treat mild hypoglycemia and may be a useful alternative to treatment with oral carbohydrate when trying to avoid unnecessary caloric intake.
UR - http://www.scopus.com/inward/record.url?scp=85026917226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026917226&partnerID=8YFLogxK
U2 - 10.1210/jc.2017-00591
DO - 10.1210/jc.2017-00591
M3 - Article
C2 - 28591776
AN - SCOPUS:85026917226
SN - 0021-972X
VL - 102
SP - 2994
EP - 3001
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 8
ER -